(Q33596335)

28 July 2017

1 reference

title

Medical therapy for Cushing's disease (English)

1 reference

ORCID Public Data File 2021

28 July 2017

1 reference

1 reference

author name string

Sonino N

series ordinal

1

1 reference

PubMed ID

10207692

28 July 2017

Boscaro M

series ordinal

2

1 reference

28 July 2017

1 March 1999

1 reference

Endocrinology and Metabolism Clinics of North America

28 July 2017

1 reference

28 July 2017

28

1 reference

28 July 2017

1

1 reference

28 July 2017

211-222

1 reference

Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Cyclical Cushing's disease and its successful control under sodium valproate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Plasma level monitoring of mitotane (o,p'-DDD) and its metabolite (o,p'-DDE) during long-term treatment of Cushing's disease with low doses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Effect of bromocriptine in pituitary-dependent Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Failure of long-term therapy with sodium valproate in Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Nyctohemeral variation and suppressibility of plasma ACTH in various stages of Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Is there a role for somatostatin and its analogs in Cushing's syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Successful control of Cushing's disease in the elderly with long term metyrapone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Effects of amino-glutethimide on adrenal function in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D and total serum calcium in hypercalcemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Unaltered stimulation of pituitary adrenocorticotrophin secretion by corticotrophin-releasing factor following sodium valproate administration in a patient with Nelson's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Pregnancy after Cyproheptadine Treatment for Cushing's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Hypolipidemic effect and mechanism of ketoconazole without and with cholestyramine in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Metyrapone in long-term management of Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Response to neurotransmitter modulating drugs in patients with Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Physiopathology of Cushing's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Effectiveness of cyproheptadine in decreasing plasma ACTH concentrations in Nelson's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Hepatic reactions associated with ketoconazole in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Adrenocorticotropin-Secreting Pituitary Adenomas Originate from the Anterior or the Intermediate Lobe in Cushing's Disease: Differences in the Regulation of Hormone Secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

The role of dopaminergic depletion in the pathogenesis of Cushing's disease and the possible consequences for medical therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Goitrous hypothyroidism induced by amino-glutethimide, anticonvulsant drug

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Treatment of Cushing's disease with adrenal blocking drugs and megavoltage therapy to the pituitary

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Mifepristone: treatment of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Sustained Remission of Cushing's Disease with Mitotane and Pituitary Irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Aminoglutethimide and ketoconazole: historical perspectives and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

The use of ketoconazole as an inhibitor of steroid production

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

From the lesson of Harvey Cushing to current knowledge: psychosocial aspects of endocrine disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Serotonin, Cushing's disease, and depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Psychosomatic aspects of Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

A role for life events in the pathogenesis of Cushing's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Effects of Cyproheptadine, Reserpine, and Synthetic Corticotropin-Releasing Factor on Pituitary Glands from Patients with Cushing's Disease*

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Cyproheptadine treatment in Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Aminoglutethimide and metyrapone in the management of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Treatment, and retreatment, of Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Mitotane increases the blood levels of hormone-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

Effect of aminoglutethimide on urinary cortisol and cortisol metabolites in adolescents with Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970064-5

7 January 2021

10.1016/S0889-8529(05)70064-5

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10207692